Nasdaq

Korro Bio, Inc. Reports Progress in KRRO-110 Clinical Study for Alpha-1 Antitrypsin Deficiency and Financial Results for 2024

Korro Bio completed dosing for its KRRO-110 study in AATD, expects interim results in 2025, and has strong financial resources. Korro Bio, Inc. has completed dosing for the first two cohorts in its ...
Nasdaq

Korro Bio Receives Orphan Drug Designation from EMA for KRRO-110 in Alpha-1 Antitrypsin Deficiency Treatment

Korro Bio, Inc., a biopharmaceutical company focused on RNA editing therapies, announced that the European Medicines Agency (EMA) has granted orphan drug designation for its investigational drug ...
Seeking Alpha

Korro Bio Highlights Data for its Lead Program in Alpha-1 Antitrypsin Deficiency (AATD) and Progress Across its RNA Editing Portfolio

CAMBRIDGE, Mass., Jan. 18, 2024 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a biopharmaceutical company focused on developing a new class of genetic medicines for both rare and highly ...
BioWorld

KRRO-110 normalizes AAT levels in models of alpha-1 antitrypsin deficiency

Alpha-1 antitrypsin deficiency (AATD) is a recessive genetic disorder caused by single nucleotide variants (SNV) in the SERPINA1 gene encoding for alpha-1 antitrypsin (AAT), with the most common ...
Reuters

Catalyst Bio - Plans To Initiate Phase 1/2 Trial Of Marzaa In Factor Vii Deficiency, Glanzmann Thrombasthenia, And Hemlibra Patients In Q4

L'Oreal's fourth-quarter sales grew 6%, it said on Thursday, as strong demand for the group's haircare and perfumes in Europe and North America compensated for barely any growth in North Asia. Reuters ...